López-Hernández MA, Montoya-Escutia P

Language: Spanish
References: 15
Page: 557-560
PDF size: 215. Kb.

ABSTRACT

Objective: To compare the rate of adherence to antiretroviral therapy in the first line in patients with depressive disorders vs those without depression.
Material and Method: A prospective study was done from January to June 2016 in patients from the HIV clinics of the Regional General Hospital No. 1 of IMSS, and the General Hospital Tacuba, in antiretroviral treatment with a first scheme, started more than six months ago, excluding patients with neurological disorders, different from depression, patients with diagnosis and/or previous treatment of depression. Patients answered the Beck questionnaire for depression and the SMAQ scale for adherence.
Results: 180 patients were evaluated with a first antiretroviral treatment regimen. It was found that 126 (70%) patients did not present depression, 36 (20%) presented depression, 15 (8.3%) presented moderate depression and 3 (1.7%) presented severe depression. Non-adherence was observed in 15.8% of patients without depression versus 55.5% of patients with depression (p = 0.01). The adherence of patients with depression was inversely proportional to the severity of the same. Regarding the viral load under the limit of suppression (‹ 40 copies/mL) in patients without depression, a higher proportion of patients with a viral load higher than 40 copies/mL was observed: 17.4% vs 15.8%, considered non-adherent by the SMAQ questionnaire.
Conclusions: Adherence decreases with the severity of depression in patients, putting the effectiveness of antiretroviral treatment at risk.

REFERENCES

1. Kaida A, Gray G, Bastos FI, Andia I, Maier M, McIntyre J, et al. The relationship between HAART use and sexual activity among HIV-positive women of reproductive age in Brazil, South Africa, and Uganda. AIDS Care 2008;20:21-25.

2. Boulle A, Ford N. Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges? Sex Transm Infect 2007;83:503-505.

3. Hacker MA, Kaida A, Hogg RS, Bastos FI. The first ten years: achievements and challenges of the Brazilian program of universal access to HIV/AIDS comprehensive management and care, 1996-2006. Cad Saude Publica 2007;23(Suppl 3):S345-359.

4. Kennedy C, O’Reilly K, Medley A, Sweat M (2007) The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care 2007;19:707-720.

5. Braitstein P, Brinkhof MW, Dabis F, Schechter M, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817-824.

6. Hogan D, Salomon J. Prevention and treatment of human immunodeficiency virus/acquired immunodeficiency syndrome in resource-limited settings. Bulletin of the World Health Organization 2005;83:135-143.

7. Murphy EL, Collier AC, Kalish LA, Assmann SF, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.

8. Paterson DL, Swindells S, Mohr J, Brester M, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV in fection. Ann Intern Med 2000;133:21-30.

9. Palella Jr. FJ, Delaney KM, Moorman AC, Loveless MO, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.

10. Kremer H, Bader A, O’Clerigh C, Bierhoff HW, Brockmeyer NH. The decision to forgot antiretroviral therapy in people living with HIV compliance as paternalism or partnership? Eur J Med Res 2004;9:61-70.

11. Magidson JF, Blashill AJ, Safren SA, Wagner GJ. Depressive symptoms, lifestyle structure, and ART adherence among HIV-infected individuals: A longitudinal mediation analysis. AIDS Behav 2014 May 30. Epub ahead of print

12. Martín-Sánchez V, Ortega-Valín L, Pérez-Simón MR, Mostaza-Fernández JL y col. Factores predictores de no adherencia al tratamiento antirretroviral de gran actividad. Enferm Infecc Microbiol Clin 2002;20(10):491-7.

13. Altice FL, Mostashari F, Friedland GH. Trust and acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001;28(1):47-58.

14. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol 2000;19(2):124-33.

15. Ahdieh-Grant L, Tarwater PM, Schneider MF, Anastos K, Cohen M, Khalsa A, et al. Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2005;38(4):500-3.